Cargando…

Myasthenia gravis in clinical practice

BACKGROUND: Myasthenia gravis is largely a treatable disease, but it can result in significant morbidity and even mortality, which can usually be avoided, or at least mitigated, with timely diagnosis and appropriate treatment of the disease. Objective: this review aims to summarize the main practica...

Descripción completa

Detalles Bibliográficos
Autores principales: Estephan, Eduardo de Paula, Baima, José Pedro Soares, Zambon, Antonio Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academia Brasileira de Neurologia - ABNEURO 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491427/
https://www.ncbi.nlm.nih.gov/pubmed/35976295
http://dx.doi.org/10.1590/0004-282X-ANP-2022-S105
_version_ 1784793275529428992
author Estephan, Eduardo de Paula
Baima, José Pedro Soares
Zambon, Antonio Alberto
author_facet Estephan, Eduardo de Paula
Baima, José Pedro Soares
Zambon, Antonio Alberto
author_sort Estephan, Eduardo de Paula
collection PubMed
description BACKGROUND: Myasthenia gravis is largely a treatable disease, but it can result in significant morbidity and even mortality, which can usually be avoided, or at least mitigated, with timely diagnosis and appropriate treatment of the disease. Objective: this review aims to summarize the main practical aspects of the diagnostic approach, treatment and care of myasthenic patients. METHODS: The authors performed a non-systematic critical review summarizing the main practical aspects of myasthenia gravis. RESULTS: Most patients with myasthenia have autoantibodies targeted at acetylcholine receptors or, less commonly, muscle-specific kinase - MuSK. Electrophysiology plays an important role in the diagnosis of neuromuscular junction dysfunction. The central clinical manifestation of myasthenia gravis is fatigable muscle weakness, which can affect eye, bulbar, respiratory, and limb muscles. With rare exceptions, patients have a good response to symptomatic treatment, but corticosteroids and/or immunosuppressants are usually also necessary to obtain good control of the manifestations of the disease. CONCLUSION: Knowledge of the peculiar aspects of their clinical and electrophysiological presentations is important for the diagnosis. Likewise, specific treatment and response time to each drug are crucial for proper care.
format Online
Article
Text
id pubmed-9491427
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Academia Brasileira de Neurologia - ABNEURO
record_format MEDLINE/PubMed
spelling pubmed-94914272022-12-08 Myasthenia gravis in clinical practice Estephan, Eduardo de Paula Baima, José Pedro Soares Zambon, Antonio Alberto Arq Neuropsiquiatr Muscle and Neuromuscular Joint Disorders BACKGROUND: Myasthenia gravis is largely a treatable disease, but it can result in significant morbidity and even mortality, which can usually be avoided, or at least mitigated, with timely diagnosis and appropriate treatment of the disease. Objective: this review aims to summarize the main practical aspects of the diagnostic approach, treatment and care of myasthenic patients. METHODS: The authors performed a non-systematic critical review summarizing the main practical aspects of myasthenia gravis. RESULTS: Most patients with myasthenia have autoantibodies targeted at acetylcholine receptors or, less commonly, muscle-specific kinase - MuSK. Electrophysiology plays an important role in the diagnosis of neuromuscular junction dysfunction. The central clinical manifestation of myasthenia gravis is fatigable muscle weakness, which can affect eye, bulbar, respiratory, and limb muscles. With rare exceptions, patients have a good response to symptomatic treatment, but corticosteroids and/or immunosuppressants are usually also necessary to obtain good control of the manifestations of the disease. CONCLUSION: Knowledge of the peculiar aspects of their clinical and electrophysiological presentations is important for the diagnosis. Likewise, specific treatment and response time to each drug are crucial for proper care. Academia Brasileira de Neurologia - ABNEURO 2022-08-12 /pmc/articles/PMC9491427/ /pubmed/35976295 http://dx.doi.org/10.1590/0004-282X-ANP-2022-S105 Text en https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License
spellingShingle Muscle and Neuromuscular Joint Disorders
Estephan, Eduardo de Paula
Baima, José Pedro Soares
Zambon, Antonio Alberto
Myasthenia gravis in clinical practice
title Myasthenia gravis in clinical practice
title_full Myasthenia gravis in clinical practice
title_fullStr Myasthenia gravis in clinical practice
title_full_unstemmed Myasthenia gravis in clinical practice
title_short Myasthenia gravis in clinical practice
title_sort myasthenia gravis in clinical practice
topic Muscle and Neuromuscular Joint Disorders
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491427/
https://www.ncbi.nlm.nih.gov/pubmed/35976295
http://dx.doi.org/10.1590/0004-282X-ANP-2022-S105
work_keys_str_mv AT estephaneduardodepaula myastheniagravisinclinicalpractice
AT baimajosepedrosoares myastheniagravisinclinicalpractice
AT zambonantonioalberto myastheniagravisinclinicalpractice